Peroxisome proliferator-activated receptors in regulation of cytochromes P450: New way to overcome multidrug resistance?

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Cizkova, Katerina ^a   Konieczna, Anna ^a   Erdosova, Bela ^a   Lichnovska, Radka ^a   Ehrmann, Jiri ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5,8,11,14 ICOSATETRAYNOIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BENZ[A]ANTHRACENE; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2J2; DRF 2519; ETHYLENE OXIDE DERIVATIVE; JTP 426467; MIFOBATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEMOLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PHENYLACETIC ACID; PHTHALIC ACID; PHYTANIC ACID; PIRINIXIC ACID; PRASTERONE; SULINDAC; TELMISARTAN; TOMELUKAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANGIOGENESIS; CANCER CELL; EMBRYO CELL; EMBRYO DEVELOPMENT; HUMAN; MITOGENESIS; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; XENOBIOTIC METABOLISM; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84869048054     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/656428     Document Type: Review

References (53)

1. Baugley B. C., Zhou J., Multidrug resistance in cancer. Multidrug Resistance in Cancer (Methods in Molecular Biology) 2010 New York, NY, USA Humana Press 1 14
2. Konieczna A., Lichnovka R., Erdosova B., Ehrmann J., The role of PPARs in MDRa lesson from embryonic development. Neoplasma 2009 56 4 279 283 2-s2.0-68149097061 10.4149/neo200904279
3. Pozzi A., Popescu V., Yang S., Mei S., Shi M., Puolitaival S. M., Caprioli R. M., Capdevila J. H., The anti-tumorigenic properties of peroxisomal proliferator-activated receptor α are arachidonic acid epoxygenase-mediated. The Journal of Biological Chemistry 2010 285 17 12840 12850 2-s2.0-77951247264 10.1074/jbc.M109.081554
4. Sahi J., Black C. B., Hamilton G. A., Zheng X., Jolley S., Rose K. A., Gilbert D., Lecluyse E. L., Sinz M. W., Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition 2003 31 4 439 446 2-s2.0-0037379266 10.1124/dmd.31.4.439 (Pubitemid 36378521)
5. Mellor H. R., Callaghan R., Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 2008 81 4 275 300 2-s2.0-43449133278 10.1159/000115967 (Pubitemid 351666917)
6. Gillet J. P., Gottesman M. M., Zhou J., Mechanisms of multidrug resistance in cancer. Multidrug Resistance in Cancer (Methods in Molecular Biology) 2010 New York, NY, USA Humana Press 47 76
7. Brown C. M., Reisfeld B., Mayeno A. N., Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metabolism Reviews 2008 40 1 1 100 2-s2.0-38949204984 10.1080/ 03602530701836662 (Pubitemid 351220646)
8. Barbier O., Fontaine C., Fruchart J. C., Staels B., Genomic and non-genomic interactions of PPAR α with xenobiotic-metabolizing enzymes. Trends in Endocrinology and Metabolism 2004 15 7 324 330 2-s2.0-4444344438 10.1016/j.tem.2004.07.007 (Pubitemid 39180007)
9. Nelson D. R., The cytochrome P450 homepage. Human Genomics 2009 4 1 59 65
10. Koukouritaki S. B., Manro J. R., Marsh S. A., Stevens J. C., Rettie A. E., McCarver D. G., Hines R. N., Developmental expression of human hepatic CYP2C9 and CYP2C19. Journal of Pharmacology and Experimental Therapeutics 2004 308 3 965 974 2-s2.0-1342344547 10.1124/jpet.103.060137 (Pubitemid 38263972)
11. Scripture C. D., Sparreboom A., Figg W. D., Modulation of cytochrome P450 activity: implications for cancer therapy. The Lancet Oncology 2005 6 10 780 789 2-s2.0-26444516024 10.1016/S1470-2045(05)70388-0 (Pubitemid 41430719)
12. Lee C. A., Neul D., Clouser-Roche A., Dalvie D., Wester M. R., Jiang Y., Jones J. P. III, Freiwald S., Zientek M., Totah R. A., Identification of novel substrates for human cytochrome P450 2J2. Drug Metabolism and Disposition 2010 38 2 347 356 2-s2.0-76149089080 10.1124/dmd.109.030270
13. McFadyen M. C. E., Melvin W. T., Murray G. I., Cytochrome P450 enzymes: novel options for cancer therapeutics. Molecular Cancer Therapeutics 2004 3 3 363 371 2-s2.0-4444223732 (Pubitemid 39193712)
14. Panigrahy D., Kaipainen A., Greene E. R., Huang S., Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Reviews 2010 29 4 723 735 2-s2.0-79952196577
15. Yan G., Chen S., You B., Sun J., Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovascular Research 2008 78 2 308 314 2-s2.0-42349117330 10.1093/cvr/cvn006 (Pubitemid 351556100)
16. Webler A. C., Popp R., Korff T., Michaelis U. R., Urbich C., Busset R., Fleming I., Cytochrome P450 2C9-indiiced angiogenesis is dependent on EphB4. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 6 1123 1129 2-s2.0-44849087722 10.1161/ATVBAHA.107.161190
17. Cheranov S. Y., Karpurapu M., Wang D., Zhang B., Venema R. C., Rao G. N., An essential role for SRC-activated STAT-3 in 14, 15-EET-induced VEGF expression and angiogenesis. Blood 2008 111 12 5581 5591 2-s2.0-47049120789 10.1182/blood-2007-11-126680
18. Webler A. C., Michaelis U. R., Popp R., Barbosa-Sicard E., Murugan A., Falck J. R., Fisslthaler B., Fleming I., Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. American Journal of Physiology 2008 295 5 C1292 C1301 2-s2.0-57349126277 10.1152/ajpcell.00230. 2008 (Pubitemid 352790340)
19. Jiang J. G., Ning Y. G., Chen C., Ma D., Liu Z. J., Yang S., Zhou J., Xiao X., Zhang X. A., Edin M. L., Card J. W., Wang J., Zeldin D. C., Dao W. W., Cytochrome P450 epoxygenase promotes human cancer metastasis. Cancer Research 2007 67 14 6665 6674 2-s2.0-34547092185 10.1158/0008-5472.CAN-06-3643 (Pubitemid 47105512)
20. Shen G. F., Jiang J. G., Fu X. N., Wang D. W., Promotive effects of epoxyeicosatrienoic acids (EETs) on proliferation of tumor cells. Chinese Journal of Cancer 2008 27 11 1130 1136 2-s2.0-77954998675
21. Bystrom J., Wray J. A., Sugden M. C., Holness M. J., Swales K. E., Warner T. D., Edin M. L., Zeldin D. C., Gilroy D. W., Bishop-Bailey D., Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS ONE 2011 6 10 e26591 10.1371/journal.pone.0026591
22. Treluyer J. M., Gueret G., Cheron G., Sonnier M., Cresteil T., Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997 7 6 441 452 2-s2.0-0030699162 (Pubitemid 27517572)
23. Enayetallah A. E., French R. A., Thibodeau M. S., Grant D. F., Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. Journal of Histochemistry and Cytochemistry 2004 52 4 447 454 2-s2.0-1842430562 (Pubitemid 38420379)
24. Leclerc J., Tournel G., Ngangue E. C. N., Pottier N., Lafitte J. J., Jaillard S., Mensier E., Lhermitte M., Broly F., Lo-Guidice J. M., Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: differential expression in non-small cell lung cancers. Biochimie 2010 92 3 292 306 2-s2.0-77649273737 10.1016/j.biochi.2009.12.007
25. Bièche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., Beaune P., de Waziers I., Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenetics and Genomics 2007 17 9 731 742 2-s2.0-34547899883 10.1097/FPC.0b013e32810f2e58 (Pubitemid 47263068)
26. DeLoia J. A., Zamboni W. C., Jones J. M., Strychor S., Kelley J. L., Gallion H. H., Expression and activity of taxane-metobolizing enzymes in ovarian tumors. Gynecologic Oncology 2008 108 2 355 360 2-s2.0-38649115996 10.1016/j.ygyno.2007.10.029
27. Gaedigk A., Baker D. W., Totah R. A., Gaedigk R., Pearce R. E., Vyhlidal C. A., Zeldin D. C., Leeder J. S., Variability of CYP2J2 expression in human fetal tissues. Journal of Pharmacology and Experimental Therapeutics 2006 319 2 523 532 2-s2.0-33751191888 10.1124/jpet.106.109215
28. Jiang J. G., Chen C. L., Card J. W., Yang S., Chen J. X., Fu X. N., Ning Y. G., Xiao X., Zeldin D. C., Wang D. W., Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Research 2005 65 11 4707 4715 2-s2.0-21144459060 10.1158/0008-5472.CAN- 04-4173 (Pubitemid 40740807)
29. Enayetallah A. E., French R. A., Grant D. F., Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. Journal of Molecular Histology 2006 37 3-4 133 141 2-s2.0-39449097368
30. Freedman R. S., Wang E., Voiculescu S., Patenia R., Bassett R. L., Deavers M., Marincola F. M., Yang P., Newman R. A., Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clinical Cancer Research 2007 13 19 5736 5744 2-s2.0-35348876122 10.1158/1078-0432.CCR-07-0583 (Pubitemid 47583898)
31. Chen C., Wei X., Rao X., Wu J., Yang S., Chen F., Ma D., Zhou J., Dackor R. T., Zeldin D. C., Wang D. W., Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. Journal of Pharmacology and Experimental Therapeutics 2011 336 2 344 355 2-s2.0-78751558396 10.1124/jpet.110.174805
32. Vanden Heuvel J. P., Peters J. M., McQueen C. A., Bond J., Ramos K., Lamb J., Guengerich F. P., Lawrence D., Walker M., Campen M., Schnellmann R., Yost G. S., Roth R. A., Ganey P., Hooser S., Richburg J., Hoyer P., Knudsen T., Daston G., Philbert M., Roberts R., Peroxisome proliferator-activated receptors. Comprehensive Toxicology (Cellular and Molecular Toxicology) 2010 2 New York, NY, USA Elsevier 145 167.
33. Chen Y., Jimenez A. R., Medh J. D., Identification and regulation of novel PPAR- γ splice variants in human THP-1 macrophages. Biochimica et Biophysica Acta 2006 1759 1-2 32 43 2-s2.0-33646480204 10.1016/j.bbaexp.2006.01. 005
34. Kota B. P., Huang T. H. W., Roufogalis B. D., An overview on biological mechanisms of PPARs. Pharmacological Research 2005 51 2 85 94 2-s2.0-11144310564 10.1016/j.phrs.2004.07.012 (Pubitemid 40040538)
35. Burns K. A., Vanden Heuvel J. P., Modulation of PPAR activity via phosphorylation. Biochimica et Biophysica Acta 2007 1771 8 952 960 2-s2.0-34547589477 10.1016/j.bbalip.2007.04.018 (Pubitemid 47198547)
36. Rees W. D., McNeil C. J., Maloney C. A., The roles of PPARs in the fetal origins of metabolic health and disease. PPAR Research 2008 2008 8 2-s2.0-38649119729 10.1155/2008/459030 459030 (Pubitemid 351171864)
37. Nadra K., Anghel S. I., Joye E., Tan N. S., Basu-Modak S., Trono D., Wahli W., Desvergne B., Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β / δ Molecular and Cellular Biology 2006 26 8 3266 3281 2-s2.0-33645802802 10.1128/MCB.26.8.3266-3281.2006
38. Barak Y., Nelson M. C., Ong E. S., Jones Y. Z., Ruiz-Lozano P., Chien K. R., Koder A., Evans R. M., PPAR γ is required for placental, cardiac, and adipose tissue development. Molecular Cell 1999 4 4 585 595 2-s2.0-0033213637 10.1016/S1097-2765(00)80209-9 (Pubitemid 29531138)
39. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., Satoh S., Nakano R., Ishii C., Sugiyama T., Kazuhiro E., Tsubamoto Y., Okuno A., Murakami K., Sekihara H., Hasegawa G., Naito M., Toyoshima Y., Tanaka S., Shiota K., Kitamura T., Fujita T., Ezaki O., Aizawa S., Nagai R., Tobe K., Kimura S., Kadowaki T., PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 1999 4 4 597 609 2-s2.0-0033212964 10.1016/S1097-2765(00)80210-5 (Pubitemid 29531139)
40. Michalik L., Wahli W., Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochimica et Biophysica Acta 2007 1771 8 991 998 2-s2.0-34547602370 10.1016/j.bbalip.2007.02.004 (Pubitemid 47198543)
41. Hall M. G., Quignodon L., Desvergne B., Peroxisome proliferator-activated receptor β / δ in the brain: facts and hypothesis. PPAR Research 2008 2008 10 2-s2.0-55949111070 10.1155/2008/780452 780452
42. Huin C., Corriveau L., Bianchi A., Keller J. M., Collet P., Krémarik-Bouillaud P., Domenjoud L., Bécuwe P., Schohn H., Ménard D., Daua M., Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. Journal of Histochemistry and Cytochemistry 2000 48 5 603 611 2-s2.0-17544387857 (Pubitemid 30233184)
43. Fournier T., Tsatsaris V., Handschuh K., Evain-Brion D., PPARs and the placenta. Placenta 2007 28 2-3 65 76 2-s2.0-33845576118 10.1016/j.placenta.2006. 04.009 (Pubitemid 44929358)
44. Abbott B. D., Wood C. R., Watkins A. M., Das K. P., Lau C. S., Peroxisome proliferator-activated receptors alpha, beta, and gamma mRNA and protein expression in human fetal tissues. PPAR Research 2010 2010 19 2-s2.0-77956803359 10.1155/2010/690907 690907
45. Rakhshandehroo M., Knoch B., Müller M., Kersten S., Peroxisome proliferator-activated receptor alpha target genes. PPAR Research 2010 2010 20 2-s2.0-78349283454 10.1155/2010/612089 612089
46. Richert L., Tuschl G., Viollon-Abadie C., Blanchard N., Bonet A., Heyd B., Halkic N., Wimmer E., Dolgos H., Mueller S. O., Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4- trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro. Drug Metabolism and Disposition 2008 36 4 702 714 2-s2.0-41549113856 10.1124/dmd.107.018358 (Pubitemid 351468377)
47. Shaban Z., Soliman M., El-Shazly S., El-Bohi K., Abdelazeez A., Kehelo K., Kim H. S., Muzandu K., Ishizuka M., Kazusaka A., Fujita S., AhR and PPAR α: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11. Xenobiotica 2005 35 1 51 68 2-s2.0-20144389721 10.1080/00498250400021804 (Pubitemid 40459217)
48. Veea R., Zachaová A., Orolin J., Strojil J., Š kottová N., Anzenbacher P., Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharmaceutics & Drug Disposition 2011 32 8 482 487
49. Zhao X., Li L. Y., PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. American Journal of Nephrology 2008 28 4 598 606 2-s2.0-45149118530 10.1159/000116885 (Pubitemid 351832447)
50. Pozzi A., Ibanez M. R., Gatica A. E., Yang S., Wei S., Mei S., Falck J. R., Capdevila J. H., Peroxisomal proliferator-activated receptor- α -dependent inhibition of endothelial cell proliferation and tumorigenesis. The Journal of Biological Chemistry 2007 282 24 17685 17695 2-s2.0-34547138678 10.1074/jbc.M701429200 (Pubitemid 47100312)
51. Wray J. A., Sugden M. C., Zeldin D. C., Greenwood G. K., Samsuddin S., Miller-Degraff L., Bradbury J. A., Holness M. J., Warner T. D., Bishop-Bailey D., The epoxygenases CYP2J2 activates the nuclear receptor PPAR α in vitro and in vivo. PLoS ONE 2009 4 10 2-s2.0-70350540660 10.1371/journal.pone.0007421 e7421
52. Ng V. Y., Huang Y., Reddy L. M., Falck J. R., Lin E. T., Kroetz D. L., Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α Drug Metabolism and Disposition 2007 35 7 1126 1134 2-s2.0-34250731775 10.1124/dmd.106.013839 (Pubitemid 46956433)
53. Prueksaritanont T., Richards K. M., Qiu Y., Strong-Basalyga K., Miller A., Li C., Eisenhandler R., Carlini E. J., Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharmaceutical Research 2005 22 1 71 78 2-s2.0-17644426320 10.1007/s11095-004-9011-5 (Pubitemid 40558148)